Magdeburger Company For Medical Studies & Services GmbH — Clinical Trial Site

13 Registered trials

7 Currently recruiting

Organisation

Magdeburger Company For Medical Studies & Services GmbH

Location

Magdeburg, Germany

Identifier

ORG-100041858

Address

Franckestrasse 1, Altstadt, 39104, Germany

Departments

Dermacare
Dermatology
N/A
NA

Clinical trials at this site (13)

Search interface

Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting

2025-521293-34-00 Moderate-to-severe hidradenitis suppurativa 4 2025-12-09
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A study to investigate improvement in pruritus of Lichen Simplex Chronicus with dupilumab injections compared with placebo in male and femal… Recruiting

2024-514737-37-00 Neurodermatitis 5 2025-03-06
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult… Recruiting

2023-505218-68-00 Moderate-Severe Atopic Dermatitis 4 2025-06-12
A clinical study comparing the efficacy and safety of a new cream containing ivermectin with the efficacy and safety of the originator produ… Recruiting

2023-505897-13-00 Papulopustular Rosacea 5 2024-12-02
Evaluation of the efficacy and safety of a new gel containing 10 mg/g Clindamycin and 0.25 mg/g Tretinoin vs. the originator Acnatac(R) 10 m… Recruiting

2023-504552-10-01 Papulopustular acne 5 2024-05-14
Clinical study to compare two cutaneous ointments with the active substance methylprednisolone aceponate 0.1% and one cutaneous ointment wit… Recruiting

2024-514548-10-01 Mild to moderate atopic dermatitis 3 2021-07-26
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 2 (STOP-PN2) Ended

2024-511881-35-00 Prurigo Nodularis 5 2024-12-17
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended

2023-508959-39-00 Moderate to Severe Plaque Psoriasis 5 2025-02-20
A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop… Ended

2023-506558-20-00 Dermatitis atopic 5 2024-06-26
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2022-501196-41-00 Dermatitis atopic 5 2024-05-29